Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Durect Corp (DRRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 217,080
  • Shares Outstanding, K 162,000
  • Annual Sales, $ 49,170 K
  • Annual Income, $ -3,700 K
  • 36-Month Beta 1.12
  • Price/Sales 4.41
  • Price/Cash Flow N/A
  • Price/Book 7.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.05
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -175.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.21 +8.26%
on 08/06/18
1.66 -21.08%
on 07/30/18
-0.25 (-16.03%)
since 07/17/18
3-Month
1.21 +8.26%
on 08/06/18
2.25 -41.78%
on 06/11/18
-0.66 (-33.50%)
since 05/17/18
52-Week
0.75 +74.67%
on 10/20/17
2.55 -48.63%
on 04/10/18
-0.33 (-20.12%)
since 08/17/17

Most Recent Stories

More News
Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025

According to a report published by Allied Market Research, the global non-alcoholic steatohepatitis (NASH) market was valued at USD 1,179 Million in 2017 and is expected to reach USD 21,478 Million by...

BTHCF : 0.0930 (-7.00%)
CNAT : 3.96 (+0.25%)
BTH.CN : 0.125 (-3.85%)
GALT : 3.87 (+0.52%)
DRRX : 1.31 (-2.24%)
GLMD : 11.45 (-0.52%)
DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2018 and provided a corporate update.

DRRX : 1.31 (-2.24%)
DURECT Corporation, Near Term PDUFA Dates, Pipeline Review and Analysts Target

NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

DRRX : 1.31 (-2.24%)
NVS : 83.04 (+1.03%)
Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

Stock Research Monitor: DEPO, DRRX, and ENDP

DRRX : 1.31 (-2.24%)
TEVA : 24.22 (+0.46%)
DEPO : 7.30 (+1.67%)
Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.

DRRX : 1.31 (-2.24%)
PTIE : 0.92 (-10.68%)
ENDP : 15.64 (-1.94%)
PFE : 42.09 (+1.62%)
Today's Research Reports on Trending Tickers: BioPharmX and DURECT

NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12...

DRRX : 1.31 (-2.24%)
BPMX : 0.16 (-3.03%)
Results of FDA Advisory Committee Meeting for REMOXY® ER

DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S....

DRRX : 1.31 (-2.24%)
PTIE : 0.92 (-10.68%)
Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

Stock Research Monitor: ZGNX, DEPO, and DRRX

DRRX : 1.31 (-2.24%)
ENDP : 15.64 (-1.94%)
ZGNX : 48.60 (+1.14%)
DEPO : 7.30 (+1.67%)
New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Durect Corporation (NASDAQ:DRRX),...

CS : 14.81 (-0.13%)
OBE : 0.99 (+1.02%)
TRP : 44.37 (+1.30%)
DRRX : 1.31 (-2.24%)
GSS : 0.72 (unch)
LOXO : 158.34 (-0.13%)
DURECT Corporation Approaching PDUFA Dates and Analysts Review

NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

DRRX : 1.31 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRRX with:

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

2nd Resistance Point 1.36
1st Resistance Point 1.33
Last Price 1.31
1st Support Level 1.28
2nd Support Level 1.26

See More

52-Week High 2.55
Fibonacci 61.8% 1.86
Fibonacci 50% 1.65
Fibonacci 38.2% 1.44
Last Price 1.31
52-Week Low 0.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar